A10BD07 - Metformin and Sitagliptin |
Propably not porphyrinogenic |
PNP |
Rationale
Neither metformin nor sitagliptin have the potential to inhibit or induce CYP enzymes. No porphyrinogenic physiological effects. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition and motivates attendance.
Therapeutic characteristics
Metformin and sitagliptin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. Vomiting and loss of appetite is potentially porphyrogenic side effects through interference with nutrition intake.
Metabolism and pharmakokinetics
Metformin: Not a Cyp-substrate. Sitagliptin: Approximately 79 per cent of sitagliptin is excreted unchanged in the urine.
Nonclinical studies indicate that the small portion of sitagliptin that undergoes biotransformation is metabolized by Cyp3A4 with the help of Cyp2C8.
In vitro data has shown that sitagliptin is not an inhibitor of CYP isozymes CYP3A4, 2C8, 2C9, 2D6, 1A2, 2C19 or 2B6, and is not an inducer of CYP3A4 and CYP1A2Experiental and clinical data indicate that there is low risk for pharmacokinetic interactions with Cyp-metabolized drugs.
IPNet drug reports
Metformin (ATC code: A10BA02) 30 reports of uneventful use. Sitagliptin: No EPNET drug reports.
References
- Scientific articles
- Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug; 12(8):648-58. PMID 20590741. #1114
- Tornio A, Niemi M, et al. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends Pharmacol Sci. 2012 Jun;33(6):312-22. PMID 22475684. #4358
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Janumet. #1116
- Other sources
- See also the monographs of metformin (ATC A10BA02) and of sitagliptin (ATC A10BH01). #1117
Similar drugs
© NAPOS 2024